Controlled release of TGF-β1 impedes rat colon carcinogenesis in vivo

International Journal of Cancer

Volumn 78, Issue 5, 1998, Pages 618-623

  Mikhailowski, Rachel ^a   Shpitz, Baruch ^c   Polak Charcon, Sylvie ^c   Kost, Yoseph ^b   Segal, Carmen ^b   Fich, Alexander ^a   Lamprecht, Sergio A ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CELL PROLIFERATION; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; GROWTH REGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

1,2-DIMETHYLHYDRAZINE; ANIMALS; COLONIC NEOPLASMS; DRUG IMPLANTS; MALE; POLYMERS; PRECANCEROUS CONDITIONS; RATS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031766360     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19981123)78:5<618::AID-IJC15>3.0.CO;2-I     Document Type: Article

References (31)

1. ALEXANDROW, M.G. and MOSES, H.L., Transforming growth factor β and cell cycle regulation. Cancer Res., 55, 1452-1457 (1995).
2. BARNARD, J.A., BEAUCHAMP, R.D., COFFEY, R.J. and MOSES, H.L., Regulation of intestinal epithelial cell growth by transforming growth factor type β. Proc. nat. Acad. Sci. (Wash.), 86, 1578-1583 (1989).
3. BARNES, C.J., HARDMAN, E., CAMERON, I.I. and LEE, M., Aspirin, but not sodium salicylate, indomethacin, or nabumeione, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats. Digest. Dis. Sci., 42, 920-926 (1997).
4. BELLELI, A., SHANY, S., LEVY, J., GUBERMAN, R. and LAMPRECHT, S.A., A protective role of 1,25-dihydroxyvitamin D3 in chemically induced rat colon carcinogenesis. Carcinogenesis, 13, 2293-2298 (1992).
5. FILMUS, J. and KERBEL, R.S., Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-β during tumor progression. Curr. Opin. Oncol., 5, 123-129 (1993).
6. FRILING, R., YASSIR, Y., LEVY, R., KOST, Y., SCHWARTZ, B., MIKHAILOWSKI, R. and LAMPRECHT, S.A., Role of transforming growth factor-β in the control of corneal neovascularization. In Vivo, 10, 59-64 (1996).
7. FYNAN, T.M. and REISS, M., Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit. Rev. Oncogenesis, 4, 493-540 (1993).
8. GOLD, L.I., SUNG, J.J., SIEBERT, J.W. and LONGAKER, M.T., Type I (RI) and type II (RII) receptors for transforming growth factor-β isoforms are expressed subsequent to transforming growth factor-β ligands during excision wound repair. Amer. J. Pathol., 150, 209-222 (1997).
9. HOSSEIN, N.M., BRATTAIN, D.E., MCKNIGHT, M.K., LEVINE, A.E. and BRATTAIN, M.G., Characterization of inhibitor effects of transforming growth factor-β on a human colon carcinoma cell line. Cancer Res., 47, 2950-2954 (1987).
10. KUROKOWA, M., LYNCH, K. and PODOLSKY, D.K., Effects of growth factors on an intestinal epithelial cell line: transforming growth factor β inhibits proliferation and stimulates differentiation. Biochem. biophys. Res. Comm., 142, 775-782 (1987).
11. LAHM, L. and ODARTCHENKO, N., Role of transforming growth factor β in colorectal cancer. Growth Factors, 9, 1-9 (1993).
12. LAMPRECHT, S.A., SCHWARTZ, B. and GLIKSMAN, A., Transforming growth factor-β in intestinal epithelial differentiation and neoplasia. Anticancer Res., 9, 1877-1882 (1989).
13. LANGER, R., Polymers for drug delivery and tissue engineering. Ann. Biomed. Eng., 23, 101-111 (1995).
14. LANGER, R., Controlled release of a therapeutic protein. Nature (Med.), 2, 742-743 (1996).
15. LAWRENCE, D.A., Transformins growth factor-β: a general review. Europ. Cytokine Netw., 7, 363-374 (1996)
16. LEVINE, A.E. and LEWIS, L.R., Transforming growth factor-β2 is an autocrine growth inhibitory factor for the Moser human colon carcinoma cell line. Cancer Lett., 68, 33-41 (1993).
17. LIN, H.Y. and LODISH, H.F., Receptors for the TGF-β superfamily: multiple polypeptides and serine/threonine kinases. Trends Cell Biol., 3, 14-19 (1993).
18. MANNING, A.M., WILLIAMS, A.C., GAME, S.M. and PARASKEVA, C., Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor β (TGF-β): conversion to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-β. Oncogene, 6, 1471-1476 (1991).
19. MARKOWITZ, S., WANG, J., MYEROFF, L., PARSONS, R., SUN, L., LUTTER-BAUGH, J., FAN, R.S., ZBOROWSKA, E., KINZLER, K.W., VOGELSTEIN, B., BRATTAIN, M. and WILLSON, J.K.V., Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science, 268, 1336-1338 (1995).
20. MARKOWITZ, S.D. and ROBERTS, A.B., Tumor suppressor activity of the TGF-β pathway in human cancers. Cytokines Growth Fact. Rev., 7, 93-102 (1996).
21. MASSAGUE, J. and POLYAK, K., Mammalian antiproliferative signals and their targets. Curr. Opin. Genet. Develop., 5, 91-96 (1995).
22. MATHIOWITZ, E., JACOB, J.S., JONG, Y.S., CARLINO, G.P., CHICKERING, D.E., CHATURVEDI, D.E., SANTOS, C.A., VIJAYARAGHAVAN, K., MONTGOMERY, S., BASSATT, M. and MORRELL, C., Biologically erodable microspheres as potential oral drug delivery systems. Nature (Lond.), 386, 410-414 (1997).
23. MIKHAILOWSKI, R., SHPITZ, B., SCHWARTZ, B., SEGAL, C. and LAMPRECHT, S.A., Putative roles of TGF-β in normal and neoplastic murine colon. Regul. Peptides, 64, 125 (1996).
24. MULDER, K.M. and BRATTAIN, M.G., Growth factor expression and response in human colon carcinoma cells. In: L.H. Augenlicht (ed.), The cell and molecular biology of colon cancer, pp. 45-67, CRC Press, Boca Raton, FL (1989).
25. 1 phase and cell cycle regulation by TGF-β Adv. Cancer Res., 71, 165-207 (1997).
26. RHINE, W.D., HSIEH, D.S.T. and LANGER, R., Polymers for sustained macromolecule release: procedures to fabricate reproducible delivery systems and control release kinetics. J. pharm. Sci., 69, 265-270 (1980).
27. ROBERTS, A.B. and SPORN, M.B., Peptides growth factors and their receptors. In: M.B. Sporn and A.B. Roberts (eds.), Handbook of experimental pharmacology, pp. 419-472, Springer, Heidelberg, Germany (1987).
28. ROBINSON, S.D., SILBERSTEIN, G.B., ROBERTS, A., FLANDERS, K.C. and DANIEL, C.W., Regulated expression and growth inhibitory effects of transforming growth factor-β isoforms in mouse mammary development. Development, 113, 867-878 (1991).
29. SHPITZ, B., HAY, K., MEDLINE, A., BRUCE, W.R., BULL, S.B., GALLINGER, S. and STERN, H.S., Natural history of aberrant crypt foci. A surgical approach. Dis. Colon Rectum, 39, 763-767 (1996).
30. VIVONA, A., SHPITZ, B., MEDLINE, A., BRUCE, W.R., HAY, K., WARD, M.A., STERN, H.S. and GALLINGER, S., K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis. Carcinogenesis, 14, 1777-1781 (1993).
31. WU, S., THEODORESCU, D., KERBEL, R.S., WILLSON, J.K.V., MULDER, K.M., HUMPHREY, L.E. and BRATTAIN, M.G., TGF-β-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J. Cell Biol., 116, 187-196 (1992).